|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammation in irritable bowel syndrome:Myth or newtreatment target?显示文摘Low-grade intestinal inflammation plays a key role in the pathophysiology of irritable bowel syndrome(IBS), and this role is likely to be multifactorial. The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice. We carried out a bibliographic search in Medline and the Cochrane Library for the period of January 1966 to December 2014, focusing on publications describing an interaction between inflammation and IBS. Several evidences demonstrate microscopic and molecular abnormalities in IBS patients. Understanding the mechanisms underlying low-grade inflammation in IBS may help to design clinical trials to test the efficacy and safety of drugs that target this pathophysiologic mechanism. | Emanuele Sinagra Giancarlo Pompei Giovanni Tomasello Francesco Cappello Gaetano Cristian Morreale Georgios Amvrosiadis Francesca Rossi Attilio Ignazio Lo Monte Aroldo Gabriele Rizzo Dario Raimondo | 2016 | World Journal of Gastroenterology2016，22，7： | 16 |
| 2 | New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond显示文摘Irritable bowel syndrome(IBS)is a chronic,recurring,and remitting functional disorder of the gastrointestinal tract characterized by abdominal pain,distention,and changes in bowel habits.Although there are several drugs for IBS,effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed.Improved understanding of pathophysiological mechanisms such as the role of impaired bile acid metabolism,neurohormonal regulation,immune dysfunction,the epithelial barrier and the secretory properties of the gut has led to advancements in the treatment of IBS.With regards to therapies for restoring intestinal permeability,multiple studies with prebiotics and probiotics are ongoing,even if to date their efficacy has been limited.In parallel,much progress has been made in targeting low-grade inflammation,especially through the introduction of drugs such as mesalazine and rifaximin,even if a better knowledge of the mechanisms underlying the low-grade inflammation in IBS may allow the design of clinical trials that test the efficacy and safety of such drugs.This literature review aims to summarize the findings related to new and investigational therapeutic agents for IBS,most recently developed in preclinical as well as Phase 1 and Phase 2clinical studies. | Emanuele Sinagra Gaetano Cristian Morreale Ghazaleh Mohammadian Giorgio Fusco Valentina Guarnotta Giovanni Tomasello Francesco Cappello Francesca Rossi Georgios Amvrosiadis Dario Raimondo | 2017 | World Journal of Gastroenterology2017，23，36： | 14 |
| 3 | Adjuvant chemotherapy for gastric cancer:Current evidence and future challenges显示文摘Gastric cancer still represents one of the major causes of cancer mortality worldwide.Patients survival is mainly related to stage,with a high proportion of patients with metastatic disease at presentation.Thus,the cure rate largely depend upon surgical resection.Despite the additional,albeit small,benefit of adjuvant chemotherapy has been clearly demonstrated,no general consensus has been reached on the best treatment option.Moreover,the narrow therapeutic index of adjuvant chemotherapy(i.e.,limited survival benefit with considerable toxicity)requires a careful assessment of expected risks and benefits for individual patients.Treatment choices vary widely based on the different geographic areas,with chemotherapy alone more often preferred in Europe or Asia and chemoradiotherapy in the United States.In the present review we discuss the current evidence and future challenges regarding adjuvant chemotherapy in curatively resected gastric cancer with particular emphasis on the recently completed landmark studies and meta-analyses.The most recent patient-level meta-analysis demonstrated the benefit of adjuvant chemotherapy over curative surgery;the same Authors also showed that disease free survival may be used as a surrogate end-point for overall survival.We finally discuss future research issues such as the need of economic evaluations,development of prognostic or predictive biomarkers,and the unmet clinical need of trials comparing perioperative chemotherapy with adjuvant treatment. | Rosalba Miceli Gianluca Tomasello Giacomo Bregni Maria Di Bartolomeo Filippo Pietrantonio | 2014 | World Journal of Gastroenterology2014，20，16： | 12 |
| 4 | Dismicrobism in inflammatory bowel disease and colorectal cancer: Changes in response of colocytes显示文摘Patients with inflammatory bowel disease(IBD)have an increased risk of 10%-15%developing colorectal cancer(CRC)that is a common disease of high economic costs in developed countries.The CRC has been increasing in recent years and its mortality rates are very high.Multiple biological and biochemical factors are responsible for the onset and progression of this pathology.Moreover,it appears absolutely necessary to investigate the environmental factors favoring the onset of CRC and the promotion of colonic health.The gut microflora,or microbiota,has an extensive diversity both quantitatively and qualitatively.In utero,the intestine of the mammalian fetus is sterile.At birth,the intestinal microbiota is acquired by ingesting maternal anal or vaginal organisms,ultimately developing into a stable community,with marked variations in microbial composition between individuals.The development of IBD is often associated with qualitative and quantitative disorders of the intestinal microbial flora(dysbiosis).The healthy human gut harbours about10 different bacterial species distributed in colony forming units which colonize the gastrointestinal tract.The intestinal microbiota plays a fundamental role in health and in the progression of diseases such as IBD and CRC.In healthy subjects,the main control of intestinal bacterial colonization occurs through gastric acidity but other factors such as endoluminal temperature,competition between different bacterial strains,peristalsis and drugs can influence the intestinal microenvironment.The microbiota exerts diverse physiological functions to include:growth inhibition of pathogenic microorganisms,synthesis of compounds useful for the trophism of colonic mucosa,regulation of intestinal lymphoid tissue and synthesis of amino acids.Furthermore,mucus seems to play an important role in protecting the intestinal mucosa and maintaining its integrity.Changes in the microbiota composition are mainly influenced by diet and age,as well as genetic factors.Increasing evidence indicates that dysbiosis favors the production of genotoxins and metabolites associated with carcinogenesis and induces dysregulation of the immune response whichpromotes and sustains inflammation in IBD leading to carcinogenesis.A disequilibrium in gut microflora composition leads to the specific activation of gut associated lymphoid tissue.The associated chronic inflammatory process associated increases the risk of developing CRC.Ulcerative colitis and Crohn’s disease are the two major IBDs characterized by an early onset and extraintestinal manifestations,such as rheumatoid arthritis.The pathogenesis of both diseases is complex and not yet fully known.However,it is widely accepted that an inappropriate immune response to microbial flora can play a pivotal role in IBD pathogenesis. | Giovanni Tomasello Pietro Tralongo Provvidenza Damiani Emanuele Sinagra Benedetto Di Trapani Marie Noelle Zeenny Inaya Hajj Hussein Abdo Jurjus Angelo Leone | 2014 | World Journal of Gastroenterology2014，20，48： | 10 |
| 5 | Outer membrane VDAC1 controls permeability transition of the inner mitochondrial membrane in cellulo during stress-induced apoptosis显示文摘电压依赖者阴离子隧道(VDAC ) 1 是 mitochondrial 的主要隧道外部膜(妈妈) 和它被建议了是渗透转变毛孔(PTP ) 的部分, mitochondrial 渗透转变(MPT ) 的一个通常认为的 multiprotein 建筑群候选人代理人。在单个实时房间水平工作,我们发现 VDAC1 的 overexpression 在 mitochondrial 触发 MPT 内部膜(MIM ) 。相反地,在 MPT 的抑制的 silencing VDAC1 表示结果由导致亚硒酸盐的氧化应力引起了。这 MOM-MIM 串音被 Cyclosporin A 和 mitochondrial Cyclophilin D,然而并非由 Bcl-2 和 Bcl-XL 调制, PTP 的陈述语气操作。VDAC1 依赖的 MPT 雇佣包含反应的氧种类和 p38-MAPK 的一个积极反馈环,并且在第二包括 Bax 激活,细胞色素 c 版本和 caspase 触发正规 apoptotic 回答 3 激活。我们的数据因此支持在 MOM 包含 VDAC1 的 PTP 建筑群的一个模型,并且显示 VDAC1 依赖的 MPT 是在氧化导致压力的 apoptosis 起一个原因的作用的在上游的机制。 | Flora Tomasello Angela Messina Lydia Lartigue Laura Schembri Chantal Medina Simona Reina Didier Thoraval Marc Crouzet Frangois Ichas Vito De Pinto Francesca De Giorgi | 2009 | Cell Research2009，19，12： | 6 |
| 6 | Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia显示文摘瞄准:在消化机关与癌症在病人评估浆液肉毒碱的层次并且把他们与另外的癌症作比较以便提供新卓见进极度瘦弱的机制。方法:55 个恶病质病人与或没有胃肠的癌症在现在的学习被注册。他们经历了平淡的实验室调查,包括在浆液在场的肉毒碱的各种各样的形式的层次的检查(即,长链的酰肉毒碱,短链的酰肉毒碱,免费肉毒碱,和全部的肉毒碱) 。这些价值与 30 个健康控制题目在好营养的地位以及与那些在 60 个癌症病人发现的那些相比。结果:当没有胃肠的癌症,有胃肠的癌症的恶病质病人与恶病质病人相比时,差别是在免费肉毒碱的 -6.8 micromol/L (P <
0.005 ) ,在长链酰肉毒碱的 0.04 micromol/L (P <
0.05 ) ,在全部的肉毒碱的 8.7 micromol/L (P <
0.001 ) 。在恶病质病人与或没有胃肠的癌症,差别是在免费肉毒碱的 12.2 micromol/L ( P <
0.001 ),在短链酰肉毒碱的 4.60 micromol/L ( P <
0.001 ),并且在长链的酰肉毒碱的 0.60 微摩尔 /L ( P <
0.005 )并且在全部的肉毒碱的 17.4 micromol/L ( P <
0.001 )。在有胃肠的癌症和健康控制题目的恶病质病人,差别是在免费肉毒碱的 15.5 micromol/L ( P <
0.001 ),在短链的酰肉毒碱的 5.2 微摩尔 /L ( P <
0.001 ),在长链酰肉毒碱的 1.0 micromol/L ( P <
0.001 ),并且在全部的肉毒碱的 21.8 micromol/L ( P <
0.001 )。结论:在终端的肉毒碱的低浆液层次肿瘤的病人由于减少的饮食的吸入极大地被减少并且损害了这种物质的内长的合成。这些低浆液肉毒碱层次也在癌症病人贡献极度瘦弱的前进。 | Mariano Malaguarnera Corrado Risino Maria Pia Gargante Giovanni Oreste Gloria Barone Anna Veronica Tomasello Mario Costanzo Matteo Angelo Cannizzaro | 2006 | World Journal of Gastroenterology2006，12，28： | 3 |
| 7 | The Human Adaption for Culture显示文摘 | Michael Tomasello | | 0，，28： | 1 |
| 8 | Bulbar compression by an ectatie vertebral artery: a novel neurovascular construct relieved by microsurgical decompression显示文摘 | Tomasello F Alafaci C Salpietro FM | 2005 | Neurosurgery2005，56，： | 1 |
| 9 | First steps toward a usage =based theory of language acquisition 显示文摘 | Tomasello M | 2000 | Cognitive linguistics2000，，11： | 1 |
| 10 | Social cognition, joint attention, and communicative competence from 9 to 15 months of age 显示文摘 | Carpenter M Nagell K Tomasello M | 1998 | Monographs of the Society for Research in Child Development1998，，： | 1 |
| 11 | Large sphenocavernous meningiomas:is there still a role for the intradural approach via the pterional transsylvian route?显示文摘 | Divitiis O Angileri FF et a1 | 2003 | Acta Neurochir(Wien)2003，145，4： | 1 |
| 12 | Altered NKG2D func- tion in NK cells induced by chronic exposure to NKG2D ligand-ex- pressing tumor cells显示文摘 | Coudert JD Zimmer J Tomasello E | 2005 | Blood2005，106，15： | 1 |
| 13 | Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D显示文摘 | Tomasello E Luc as M | 2002 | Nat Immunol2002，3，12： | 1 |
| 14 | A pilot phase II studyof chemotherapy with oxaliplatin, folinic acid,5-fluorouraciland irinotecan in metastatic gastric cancer显示文摘 | Chiesa MD Buti S Tomasello G | 2007 | Tumori2007，93，3： | 1 |
| 15 | Hsp60 and Hspl0 increase in colon mucosa of Crohn's disease and ulcerative colitis显示文摘 | Rodolico V Tomasello G Zerill M | 2010 | Cell Stress Chaperones2010，15，6： | 1 |
| 16 | p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulatin factor显示文摘 | Poggi A Tomasello E Ferrero E | 1998 | Eur J Immunol1998，28，7： | 1 |
| 17 | p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by GM-CSF显示文摘 | Poggi A Tomasello E Ferrero E | 1998 | Eur J Immunol1998，28，7： | 1 |
| 18 | In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry显示文摘 | Galassi AR Tomasello SD Reifart N | 2011 | Eurolntervention2011，7，4： | 1 |
| 19 | Functions of natu- ral killer cells显示文摘 | Vivier E Tomasello E Baratin M | 2008 | Nat Immunol2008，9，5： | 1 |
| 20 | Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? 显示文摘 | Vivier E Tomasello E Paul P | 2002 | Curr Opin Immunol2002，14，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员